The San Antonio Breast Cancer Symposium (SABCS) 2022

HER Speaker Series: SABCS Poster ReviewПодробнее

Harnessing the Power of Predictive BiomarkersПодробнее

Bay Area Breast Cancer Forum: Updates from San Antonio Breast Cancer Symposium.Подробнее

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

BCI as a Predictive Biomarker for Extended Endocrine Therapy BenefitПодробнее

BC patients who interrupted ET to pursue pregnancy did not have worse short-term recurrence ratesПодробнее

Adjuvant ET +/- 1 year of everolimus in patients with high-risk HR-positive, HER2-negative BCПодробнее

PTCy/Tac/MMF as the new standard for GVHD prophylaxis in reduced intensity conditioningПодробнее

Treatment decision guided by CTC count may improve long-term outcomes for patients with MBCПодробнее

Independent validation of the HER2DX genomic test in HER2-positive breast cancerПодробнее

Natera Signatera Product Theater SABCS 2022: ctDNA UtilityПодробнее

Dr. Melinda Telli | San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

Natera Signatera Product Theater at SABCS 2022Подробнее

SABCS 2022 - Exact Sciences Announces Data Supporting Future of Breast Cancer Care ContinuumПодробнее

Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNAПодробнее

Dr. Andrea Barrio | View From The Trenches | San Antonio Breast Cancer Symposium 2022Подробнее

Dr. Shom Goel |San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

Dr. Marleen Kok | San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

Natera Signatera Product Theater at SABCS 2022: MRDПодробнее

Breast Cancer Breakthroughs: The road to achieving clinical trial access for allПодробнее